New hope for pancreatic cancer: targeted drug plus chemo shows promise in early trial
NCT ID NCT06396091
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This early-stage study tests a new drug called zolbetuximab combined with standard chemotherapy for people with advanced pancreatic cancer that has spread. The drug targets a protein on cancer cells to help the immune system attack them. The main goal is to see if the combination is safe and tolerable for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.